What is Septerna?
Septerna operates at the intersection of advanced molecular biology and pharmaceutical development. The company is dedicated to unlocking the therapeutic potential of G protein-coupled receptors (GPCRs), a class of proteins that represent a significant portion of current drug targets but have historically been difficult to address with traditional small-molecule approaches. Through its Native Complex Platform, Septerna is able to stabilize and study these receptors in their native environment, facilitating the discovery of novel, oral drug candidates. This scientific differentiation allows the firm to pursue high-impact indications in inflammation and metabolic health, effectively bridging the gap between complex biological research and scalable clinical applications.
How much funding has Septerna raised?
Septerna has raised a total of $538M across 3 funding rounds:
Series A
$100M
Series B
$150M
Stock Offering
$288M
Series A (2022): $100M with participation from Samsara BioCapital, BVF Partners, Third Rock Ventures, and Invus Financial Advisors
Series B (2023): $150M led by Samsara BioCapital, Third Rock Ventures, and RA Capital Management
Stock Issuance/Offering (2024): $288M supported by Wells Fargo Securities, Cowen, and Cantor Fitzgerald
Key Investors in Septerna
Samsara BioCapital
A specialized investment firm focused on creating transformative therapeutics by partnering with scientists and drug developers to drive biopharmaceutical innovation.
Third Rock Ventures
A healthcare venture firm that combines scientific vision with operational expertise to launch and build companies focused on disruptive medicine.
RA Capital Management
A multi-stage investment manager utilizing evidence-based strategies and its internal TechAtlas think tank to support life science companies from lab to clinic.
What's next for Septerna?
With the successful completion of this recent financing, Septerna is well-positioned to transition its lead candidates further through the clinical pipeline. The strategic allocation of these funds will likely focus on expanding internal research capabilities and strengthening partnerships to broaden the reach of its GPCR-targeting portfolio. As the company matures, the focus will shift toward achieving key clinical milestones that validate the efficacy of its platform in human trials. Investors and industry observers will be monitoring the firm's ability to translate its robust preclinical data into tangible patient outcomes, a critical step for long-term value creation in the competitive biotechnology sector.
See full Septerna company page
